Pre-made Tarlatamab benchmark antibody ( Bispecific scFv, anti-DLL3;CD3E therapeutic antibody, Anti-SCDO1;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-552

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-552 Category Tags ,

Product Details

Pre-Made Tarlatamab biosimilar, Bispecific scFv, Anti-DLL3;CD3E Antibody: Anti-SCDO1;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tarlatamab is a half-life extended delta-like protein 3 (DLL3)/anti-CD3 bispecific T-cell engager (HLE BiTE) antibody construct, being developed by Amgen for the treatment of small cell lung cancer, neuroendocrine prostate cancer and metastatic melanoma.

Products Name (INN Index)

Pre-Made Tarlatamab biosimilar, Bispecific scFv, Anti-DLL3;CD3E Antibody: Anti-SCDO1;T3E/TCRE/IMD18 therapeutic antibody

INN Name

Tarlatamab

Target

DLL3,CD3E

Format

Bispecific scFv

Derivation

Bispecific antibody

Species Reactivity

Human

CH1 Isotype

na;na

VD LC

Kappa,Lambda

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Active

100% SI Structure

None;None

99% SI Structure

None;None

95-98% SI Structure

None;None

Year Proposed

2020

Companies

Amgen

Conditions Approved

NA

Conditions Active

Small cell lung cancer

Conditions Discontinued

NA

Development Tech

BiTE Technology

Previous Name

NA

Gm Offical Target Name

DLL3,CD3E

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide